{"DataElement":{"publicId":"3354944","version":"1","preferredName":"Prostate Cancer Progression Post Hormone Therapy Type","preferredDefinition":"Text term to describe the type of disease progression after the initiation of hormonal therapy.","longName":"3351720v1.0:3354941v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3351720","version":"1","preferredName":"Prostate Cancer Progression Post Hormone Therapy","preferredDefinition":"The walnut shaped accessory sex gland of the male reproductive system. It is located in the pelvis just below the bladder, surrounding the prostatic part of the urethra. The prostate gland secretes a fluid which is part of the semen._A pathologic process in which alterations at the molecular level result in a more aggressive cytologic and phenotypic profile and clinical course of a malignant neoplasm._Happening at a time subsequent to a reference time; later in time or order._Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level. The treatment may include administration of hormones or hormone analogs to the patient, or decreasing the level of hormones in the body by using hormone antagonists, or hormone ablation therapy. The concept covers but not limited to: intermittent or permanent hormone suppression or ablation in treatment of hormone-dependent tumors, hormone replacement therapy of any kind, hormonal component of gender reassignment therapy, hormonal contraception, surgical and radiation castration.","longName":"3351717v1.0:3351718v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"3351717","version":"1","preferredName":"Prostate Gland Cancer Progression","preferredDefinition":"The walnut shaped accessory sex gland of the male reproductive system. It is located in the pelvis just below the bladder, surrounding the prostatic part of the urethra. The prostate gland secretes a fluid which is part of the semen.:A pathologic process in which alterations at the molecular level result in a more aggressive cytologic and phenotypic profile and clinical course of a malignant neoplasm.","longName":"C12410:C19987","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Gland","conceptCode":"C12410","definition":"The walnut shaped accessory sex gland of the male reproductive system. It is located in the pelvis just below the bladder, surrounding the prostatic part of the urethra. The prostate gland secretes a fluid which is part of the semen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cancer Progression","conceptCode":"C19987","definition":"A pathologic process in which alterations at the molecular level result in a more aggressive cytologic and phenotypic profile and clinical course of a malignant neoplasm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B65BB4F3-5F6E-218B-E040-BB89AD4337DD","latestVersionIndicator":"Yes","beginDate":"2012-01-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-12","modifiedBy":"ONEDATA","dateModified":"2012-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3351718","version":"1","preferredName":"Post Endocrine Therapy","preferredDefinition":"Happening at a time subsequent to a reference time; later in time or order.:Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level. The treatment may include administration of hormones or hormone analogs to the patient, or decreasing the level of hormones in the body by using hormone antagonists, or hormone ablation therapy. The concept covers but not limited to: intermittent or permanent hormone suppression or ablation in treatment of hormone-dependent tumors, hormone replacement therapy of any kind, hormonal component of gender reassignment therapy, hormonal contraception, surgical and radiation castration.","longName":"C38008:C15445","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Post","conceptCode":"C38008","definition":"Happening at a time subsequent to a reference time; later in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Hormone Therapy","conceptCode":"C15445","definition":"Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B65BB4F3-5F7F-218B-E040-BB89AD4337DD","latestVersionIndicator":"Yes","beginDate":"2012-01-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-12","modifiedBy":"ONEDATA","dateModified":"2012-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B65BB4F3-5F90-218B-E040-BB89AD4337DD","latestVersionIndicator":"Yes","beginDate":"2012-01-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-12","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Released per approval by B.McClure-Shimel. mc 1/18/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3354941","version":"1","preferredName":"Cancer Progression Post Hormone Therapy Type","preferredDefinition":"A pathologic process in which alterations at the molecular level result in a more aggressive cytologic and phenotypic profile and clinical course of a malignant neoplasm._Happening at a time subsequent to a reference time; later in time or order._Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level. The treatment may include administration of hormones or hormone analogs to the patient, or decreasing the level of hormones in the body by using hormone antagonists, or hormone ablation therapy. The concept covers but not limited to: intermittent or permanent hormone suppression or ablation in treatment of hormone-dependent tumors, hormone replacement therapy of any kind, hormonal component of gender reassignment therapy, hormonal contraception, surgical and radiation castration._Type; a subdivision of a particular kind of thing.","longName":"3354941v1.0","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"25","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Distant Metastases","valueDescription":"Distant Metastasis","ValueMeaning":{"publicId":"2568046","version":"1","preferredName":"Distant Metastasis","longName":"2568046","preferredDefinition":"Refers to cancer that has spread from the original (primary) tumor to distant organs or distant lymph nodes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Distant Metastasis","conceptCode":"C18206","definition":"A biological process that involves the transfer and growth of cancer cells from the site of the primary tumor. Relocation of malignant cells during metastasis can be restricted to movement within a specific tissue/organ or may entail migration to a distal locus within the body. This phenotype is a characteristic of all malignant tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D6DB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-01-12","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B6CF6993-A578-193F-E040-BB89AD434FFC","beginDate":"2012-01-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-18","modifiedBy":"ONEDATA","dateModified":"2012-01-18","deletedIndicator":"No"},{"value":"Biochemical Recurrence","valueDescription":"PSA Failure","ValueMeaning":{"publicId":"3354943","version":"1","preferredName":"PSA Failure","longName":"3354943","preferredDefinition":"A rise in the blood level of PSA (prostate-specific antigen) in prostate cancer patients after treatment with surgery or radiation. PSA failure may occur in patients who do not have symptoms. It may mean that the cancer has come back.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"PSA Failure","conceptCode":"C93229","definition":"An increase in serum prostate-specific antigen (PSA) levels following treatment for prostate cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6CF6993-A586-193F-E040-BB89AD434FFC","latestVersionIndicator":"Yes","beginDate":"2012-01-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-18","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B6CF6993-A59F-193F-E040-BB89AD434FFC","beginDate":"2012-01-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-18","modifiedBy":"ONEDATA","dateModified":"2012-01-18","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008563","version":"1","preferredName":"Therapy Results","preferredDefinition":"the results or effects (does not include CTC Adverse Events) of therapeutic agents or procedures administered to the patient.","longName":"TX_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6690D31-4081-494A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-06","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-02-11","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3354940","version":"1","preferredName":"Cancer Progression Post Endocrine Therapy Type","preferredDefinition":"A pathologic process in which alterations at the molecular level result in a more aggressive cytologic and phenotypic profile and clinical course of a malignant neoplasm.:Happening at a time subsequent to a reference time; later in time or order.:Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level. The treatment may include administration of hormones or hormone analogs to the patient, or decreasing the level of hormones in the body by using hormone antagonists, or hormone ablation therapy. The concept covers but not limited to: intermittent or permanent hormone suppression or ablation in treatment of hormone-dependent tumors, hormone replacement therapy of any kind, hormonal component of gender reassignment therapy, hormonal contraception, surgical and radiation castration.:Type; a subdivision of a particular kind of thing.","longName":"C19987:C38008:C15445:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cancer Progression","conceptCode":"C19987","definition":"A pathologic process in which alterations at the molecular level result in a more aggressive cytologic and phenotypic profile and clinical course of a malignant neoplasm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Post","conceptCode":"C38008","definition":"Happening at a time subsequent to a reference time; later in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Hormone Therapy","conceptCode":"C15445","definition":"Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6CF6993-A547-193F-E040-BB89AD434FFC","latestVersionIndicator":"Yes","beginDate":"2012-01-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-18","modifiedBy":"ONEDATA","dateModified":"2012-01-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6CF6993-A558-193F-E040-BB89AD434FFC","latestVersionIndicator":"Yes","beginDate":"2012-01-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-18","modifiedBy":"COOPERM","dateModified":"2012-01-20","changeDescription":"Released per approval by B.McClure-Shimel. mc 1/20/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2756809","version":"1","longName":"TCGA (The Cancer Genome Atlas)","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6044923","version":"1","longName":"Active CDEs as of March 2017","context":"NCIP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Type of Progression After Hor","type":"Preferred Question Text","description":"Type of Progression After Hormonal Therapy","url":null,"context":"NCIP"}],"origin":"TCGA:The Cancer Genome Atlas","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6CF6993-A5B5-193F-E040-BB89AD434FFC","latestVersionIndicator":"Yes","beginDate":"2012-01-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-18","modifiedBy":"TSESU","dateModified":"2018-07-13","changeDescription":"Released per TCGA approval by B.McClure-Shimel. mc 1/20/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}